Neidio i’r brif dudalen lywio Neidio i chwilio Neidio i’r prif gynnwys

Nedd8-activating enzyme inhibitor MLN4924 provides synergy with mitomycin C through interactions with ATR, BRCA1/BRCA2, and chromatin dynamics pathways

  • Khristofer Garcia
  • , Jonathan L Blank
  • , David C Bouck
  • , Xiaozhen J Liu
  • , Darshan S Sappal
  • , Greg Hather
  • , Katherine Cosmopoulos
  • , Michael P Thomas
  • , Mike Kuranda
  • , Michael D Pickard
  • , Ray Liu
  • , Syamala Bandi
  • , Peter G Smith
  • , Eric S Lightcap
  • Takeda Pharmaceuticals International Co.

Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

Crynodeb

MLN4924 is an investigational small-molecule inhibitor of the Nedd8-activating enzyme currently in phase I clinical trials. MLN4924 induces DNA damage via rereplication in most cell lines. This distinct mechanism of DNA damage may affect its ability to combine with standard-of-care agents and may affect the clinical development of MLN4924. As such, we studied its interaction with other DNA-damaging agents. Mitomycin C, cisplatin, cytarabine, UV radiation, SN-38, and gemcitabine demonstrated synergy in combination with MLN4924 in vitro. The combination of mitomycin C and MLN4924 was shown to be synergistic in a mouse xenograft model. Importantly, depletion of genes within the ataxia telangiectasia and Rad3 related (ATR) and BRCA1/BRCA2 pathways, chromatin modification, and transcription-coupled repair reduced the synergy between mitomycin C and MLN4924. In addition, comet assay demonstrated increased DNA strand breaks with the combination of MLN4924 and mitomycin C. Our data suggest that mitomycin C causes stalled replication forks, which when combined with rereplication induced by MLN4924 results in frequent replication fork collisions, leading to cell death. This study provides a straightforward approach to understand the mechanism of synergy, which may provide useful information for the clinical development of these combinations.

Iaith wreiddiolSaesneg
Tudalennau (o-i)1625-35
Nifer y tudalennau11
CyfnodolynMol. Cancer Ther.
Cyfrol13
Rhif cyhoeddi6
Dyddiad ar-lein cynnar26 Maw 2014
Dynodwyr Gwrthrych Digidol (DOIs)
StatwsCyhoeddwyd - Meh 2014
Cyhoeddwyd yn allanolIe

Ôl bys

Gweld gwybodaeth am bynciau ymchwil 'Nedd8-activating enzyme inhibitor MLN4924 provides synergy with mitomycin C through interactions with ATR, BRCA1/BRCA2, and chromatin dynamics pathways'. Gyda’i gilydd, maen nhw’n ffurfio ôl bys unigryw.

Dyfynnu hyn